Lundbeck To Buy Chelsea Therapeutics | Chemical & Engineering News
Volume 92 Issue 19 | p. 17 | Concentrates
Issue Date: May 12, 2014

Lundbeck To Buy Chelsea Therapeutics

Department: Business
Keywords: neurological disorder, accelerated approval

Lundbeck, the Danish drug firm specializing in neurological and brain diseases, has agreed to acquire Charlotte, N.C.-based Chelsea Therapeutics for $530 million up front. The firm will pay Chelsea shareholders an additional $128 million if Chelsea’s FDA-approved Northera meets unspecified commercial milestones by 2017. Northera is a treatment for light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by autonomic failure, a condition associated with Parkinson’s disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment